Tanya Dorff, MD

Tanya Dorff, MD, discusses the main findings from a phase 1 study of patients with metastatic castration-resistant prostate cancer.

Oncologists share some final thoughts on lutetium-PSMA-617 and novel agents to look out for in prostate cancer treatment.

Alicia Morgans, MD, MPH, presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.

Experts share their thoughts on sequencing hormonal agents and patient selection for clinical trials.

A review of recent data from the TheraP trial.

Tanya Dorff, MD, explains safety and efficacy data from the CARD trial.

Dr Tanya Dorff presents the case of a 72-year-old man with metastatic hormone-sensitive prostate cancer.

A review of data from the ALSYMPCA clinical trial on the use of radium-223 for prostate cancer treatment.

A discussion on the use of lutetium-PSMA-617 for prostate cancer treatment.

Experts in genitourinary oncology present data from the VISION clinical trial, studying patients with PSMA-positive metastatic castration-resistant prostate cancer.

Dr Ulka Vaishampayan presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.

Phillip J. Koo, MD, provides a detailed explanation of the process of PSMA-PET imaging scans for prostate cancer.

Tanya Dorff, MD, reviews guidelines for initial risk stratification of patients with localized prostate cancer, and the choices in imaging strategies.

Tanya Dorff, MD, discusses the phase 1 study of chimeric antigen receptor T-cell therapy in patients with metastatic castration-resistant prostate cancer.

Tanya Dorff, MD, discusses the recent findings from a phase 1 clinical trial which explored the use of chimeric antigen receptor T-cell therapy in patients with prostate cancer.

Tanya Dorff, MD, discusses the current treatment modalities for prostate cancer and the hope that chimeric antigen receptor T cells will improve outcomes.

Tanya Dorff, MD, discusses the introduction of chimeric antigen receptor T-cell therapy into the prostate cancer landscape.

During a Targeted Oncology Case-Based Peer Perspectives Roundtable, Tanya Dorff, MD, reviews the available treatment options for nonmetastatic castration-resistant prostate cancer to select a treatment for 57-year-old patient.

Tanya Dorff, MD, discusses recent data with olaparib (Lynparza) in castration-resistant prostate cancer and the future role of PARP inhibitors in this disease.<br /> &nbsp;